More on Amgen (AMGN): Q4 misses slightly on a per share basis due to higher sales costs, but beats on revenue. Overall sales growth was positive, with strong performance coming from its two heavyweight drugs, Xgeva and Prolia, plus decent showings as well from Neupogen and Neulasta. The Company expects FY12 revenue in the range of $16.1B - $16.5B. Shares +0.8% AH.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs